Skip to main content

Table 1 Characteristics of BBD histology among breast cancer cases, overall and by age and ER status at breast cancer diagnosis (N = 514)

From: Risk factors for breast cancer development by tumor characteristics among women with benign breast disease

    Age at breast cancer diagnosis ER status
Cases ≤ 50 years (N = 69) > 50 years (N = 445) Pa ER+ (N = 391) ER− (N = 64) Pa
N % N % N % N % N %
Age at BBD, years
 < 40 90 17.5 41 59.4 49 11.0 < 0.0001 61 15.6 13 20.3 0.83
 40–49 141 27.4 28 40.6 113 25.4   113 28.9 17 26.6  
 50–59 145 28.2 0 0 145 32.6   111 28.4 19 29.7  
 60–69 86 16.7 0 0 86 9.3   65 16.6 8 12.5  
 ≥ 70 52 10.1 0 0 52 11.7   41 10.5 7 10.9  
 Mean (SD) 52.2 (12.5) 37.5 (6.9) 54.4 (11.6)   52.4 (12.5) 51.7 (12.9)  
 Median (IQR) 51.5 (42.6, 60.8) 39.0 (34.9, 42.9) 53.6 (46.1, 62.1)   51.7 (42.8, 61.0) 50.6 (42.8, 59.8)  
Year of BBD diagnosis        0.062      0.92
 1971–1979 95 18.5 19 27.5 76 17.1   50 12.8 10 15.6  
 1980–1989 173 33.7 16 23.2 157 35.3   134 34.3 20 31.3  
 1990–1999 161 31.3 25 36.2 136 30.6   134 34.3 22 34.4  
 2000–2006# 85 16.5 9 13.0 76 17.1   73 18.7 12 18.8  
BBD histology        0.22      0.39
 Normal/non-proliferative 324 63.0 50 72.5 274 61.6   243 62.2 43 67.2  
 Proliferative without atypia 163 31.7 16 23.2 147 33.3   127 32.5 20 31.3  
 Proliferative with atypia 27 5.3 3 4.4 24 5.4   21 5.4 1 1.6  
Year of breast cancer diagnosis       < 0.0001      0.53
 1973–1990 72 14.1 22 31.9 51 11.4   21 5.4 3 4.7  
 1991–1995 68 13.2 10 14.5 58 13.0   49 12.5 12 18.8  
 1996–2000 101 19.7 17 24.6 84 18.8   81 20.7 17 26.6  
 2001–2005 116 22.6 11 15.9 106 23.7   104 26.6 12 18.8  
 2006–2010 106 20.6 5 7.3 101 22.6   91 23.3 14 21.9  
 2011–2013 51 9.9 4 5.8 47 10.6   45 11.5 6 9.4  
Years from BBD to breast cancer diagnosis        < 0.0001      0.55
 ≤ 10 284 55.3 54 78.3 230 51.7   198 50.6 35 54.7  
 > 10 230 44.8 15 21.7 215 48.3   193 49.4 29 45.3  
 Mean (SD) 10.8 (7.9) 7.3 (6) 11.4 (8)   11.6 (8) 10.5 (8.3)  
 Median (IQR) 9.0 (4.4, 15.8) 5.6 (2.9, 9.4) 9.8 (4.7, 16.3)   10.0 (5.3, 16.4) 8.7 (3.3, 15.7)  
Tumor size/mm        0.13      0.63
 < 10 143 28.9 26 37.7 117 27.5   90 23.9 16 26.2  
 10–20 211 42.6 29 42.0 182 42.7   173 45.9 24 39.3  
 > 20 141 28.5 14 20.3 127 29.8   114 30.2 21 34.4  
 Missing 19   0   19    14   3   
Tumor gradec        0.14      < 0.0001
 Well differentiated 141 34.7 14 31.8 127 34.9   134 39.3 5 8.6  
 Moderately differentiated 159 38.9 13 29.6 146 40.1   149 43.7 6 10.3  
 Poorly differentiated 108 26.4 17 38.6 91 25.0   58 17.0 47 81.0  
 Not determined 106   25   81    50   6   
ER        0.026     
 Negative 64 14.1 12 24.5 52 12.8   
 Positive 391 85.9 37 75.5 354 87.2   
 Missing/unknown 59   20   39    
PR        0.53      < 0.0001
 Negative 131 28.9 16 32.7 115 28.4   73 18.7 58 90.6  
 Positive 323 71.2 33 67.4 290 71.6   317 81.3 6 9.4  
 Missing/unknown 60   20   40    1   0   
HER2d        0.99b      0.0028
 Negative 224 79.4 17 73.9 207 79.9   203 81.5 20 62.5  
 Positive 50 17.7 4 17.4 46 17.8   38 15.3 12 37.5  
 Equivocal 8 2.8 2 8.7 6 2.3   8 3.2 0 0.0  
 Missing/unknown 232   46   186    142   32   
Regional lymph nodes        0.98      0.11
 Negative 337 73.6 47 73.4 230 73.6   264 74.6 36 64.3  
 Positive 121 26.4 17 26.6 104 26.4   90 25.4 20 35.7  
 Missing 56   5   51    37   8   
Tumor histology        0.54b      0.14b
 Ductal 439 83.5 59 85.5 370 83.2   322 82.4 54 84.4  
 Lobular 48 9.3 8 11.6 40 9.0   39 10.0 4 6.3  
 Mixed ductal/lobular 26 5.1 2 2.9 24 5.4   23 5.9 2 3.1  
 Others 11 2.1 0 0.0 11 2.5   7 1.8 4 6.3  
Tumor stage        0.46b      0.30b
 I 262 58.0 32 62.8 230 57.4   223 59.3 29 47.5  
 II 150 33.2 13 25.5 137 34.2   120 31.9 25 41.0  
 III 29 6.4 4 7.8 25 6.2   24 6.4 5 8.2  
 IV 11 2.4 2 3.9 9 2.2   9 2.4 2 3.3  
 Missing 62   18   44    15   3   
  1. Among all cases, 13.4% were diagnosed with breast cancer by 50 years old versus 86.6% were diagnosed after age at 50 years. Fifty-nine cases who had missing ER status were excluded from analyses with ER status. BBD benign breast disease, ER estrogen receptor status, HER2 human epidermal growth factor, IQR inter-quartile range, PR progesterone receptor status, SD standard deviation. aP-values from the chi-square test except where noted; cases with missing tumor characteristics were excluded from reported percentage and tests; P-values less than 0.05 are in bold font. bP-values from the Fisher exact test. cPatients with tumor grade as “not determined” were excluded from analysis. dPatients with equivocal HER2 were excluded from the analysis. Involution and columnar cell lesion associations were adjusted for all factors above the line indicated in OR*. #One control had a BBD diagnosis in 2012